Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamune and Herceptin in HER2+ Metastatic Breast Cancer
NCT00411788Phase 2Completed
- Sponsor
- Yale University
- Start
- Dec 2006
- Primary completion
- May 2010
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-sirolimus in HER2-positive metastatic breast cancer, sponsored by Yale University. Started Dec 2006; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
HER2-positive metastatic breast cancer
Beyond the preview
Go deeper on NCT00411788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411788.